Kymera Therapeutics (KYMR) Cash from Financing Activities (2019 - 2026)

Kymera Therapeutics (KYMR) has reported Cash from Financing Activities for 8 consecutive years, with $18.8 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Cash from Financing Activities rose 7174.81% year-over-year to $18.8 million; the TTM figure through Mar 2026 stood at $1.0 billion (up 295.23% YoY), while the FY2025 annual figure was $990.7 million, up 62.72% from the prior year.
• Cash from Financing Activities slipped to $18.8 million in Q1 2026 per KYMR's latest filing, from $705.2 million in the prior quarter.
• Across five years, Cash from Financing Activities topped out at $705.2 million in Q4 2025 and bottomed at -$206000.0 in Q3 2023.
• Historically, Cash from Financing Activities has averaged $104.4 million across 5 years, with a median of $2.0 million in 2022.
• Annual changes were most pronounced in 2023 — Cash from Financing Activities sank 100.14% — and 2024, when it jumped 121904.85%.
• Kymera Therapeutics' Cash from Financing Activities stood at $2.0 million in 2022, then slipped by 0.97% to $1.9 million in 2023, then soared by 42.97% to $2.8 million in 2024, then soared by 25405.21% to $705.2 million in 2025, then sank by 97.34% to $18.8 million in 2026.
• Business Quant data shows KYMR's Cash from Financing Activities at $18.8 million in Q1 2026, $705.2 million in Q4 2025, and $39.5 million in Q3 2025.